Copyright
©The Author(s) 2017.
World J Gastroenterol. May 21, 2017; 23(19): 3496-3504
Published online May 21, 2017. doi: 10.3748/wjg.v23.i19.3496
Published online May 21, 2017. doi: 10.3748/wjg.v23.i19.3496
Table 3 Diagnostic value of autoantibodies and different combinations in α-fetoprotein-negative hepatocellular carcinoma
| Type of sera | Sensitivity | Specificity | Accuracy |
| NPM1 | 21.4% | 95.6% | 80.9% |
| 14-3-3zeta | 19.6% | 95.2% | 80.2% |
| MDM2 | 19.6% | 93.0% | 78.4% |
| NPM1 + 14-3-3zeta | 25.0% | 94.3% | 80.7% |
| NPM1 + MDM2 | 30.4% | 93.0% | 80.7% |
| 14-3-3zeta + MDM2 | 25.0% | 92.1% | 78.8% |
| NPM1 + 14-3-3zeta + MDM2 | 30.4% | 91.6% | 79.5% |
- Citation: Wang T, Liu M, Zheng SJ, Bian DD, Zhang JY, Yao J, Zheng QF, Shi AM, Li WH, Li L, Chen Y, Wang JH, Duan ZP, Dong L. Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma. World J Gastroenterol 2017; 23(19): 3496-3504
- URL: https://www.wjgnet.com/1007-9327/full/v23/i19/3496.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i19.3496